77 related articles for article (PubMed ID: 16186590)
1. Is there a role for routine p53 testing in colorectal cancer?
Hoff PM
J Clin Oncol; 2005 Oct; 23(30):7395-6. PubMed ID: 16186590
[No Abstract] [Full Text] [Related]
2. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
3. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
[TBL] [Abstract][Full Text] [Related]
4. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
[TBL] [Abstract][Full Text] [Related]
5. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas.
Kim JC; Roh SA; Cho DH; Kim TW; Yoon SN; Kim CW; Yu CS; Kim SY; Kim YS
Anticancer Res; 2009 Aug; 29(8):3115-23. PubMed ID: 19661324
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
[TBL] [Abstract][Full Text] [Related]
7. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma.
Lagerstedt KK; Kressner U; Lönnroth C; Nordgren S; Lundholm K
Int J Oncol; 2005 Dec; 27(6):1707-15. PubMed ID: 16273227
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?
Tan XL; Nieters A; Hoffmeister M; Beckmann L; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2007 Aug; 17(8):639-45. PubMed ID: 17622940
[TBL] [Abstract][Full Text] [Related]
9. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
[TBL] [Abstract][Full Text] [Related]
10. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Liu Y; Bodmer WF
Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
[TBL] [Abstract][Full Text] [Related]
11. [The expression of mutation p53 gene from circulating cancer cells of peripheral blood and the clinical significance in detecting the patients with colorectal cancer].
Ma GJ; Zhou JN; Shen ZL; Chen SQ; Zhu YQ; Wu XL; Xue KX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):186-8. PubMed ID: 16604493
[TBL] [Abstract][Full Text] [Related]
12. [Current concepts in the genetics of hereditary and sporadic colorectal cancer and the role of genetics in clinical practice: sporadic and IBD-associated colorectal tumors, significance of genetic tests in diagnosis, prognosis and assessment of chemotherapy outcome].
Lakatos PL; Lakatos L
Orv Hetil; 2006 Mar; 147(10):449-55. PubMed ID: 16573174
[TBL] [Abstract][Full Text] [Related]
13. Different p53 mutation patterns in colorectal tumors from smokers and nonsmokers.
Huang CC; Cheng YW; Chen MC; Lin YS; Chou MC; Lee H
Environ Mol Mutagen; 2006 Aug; 47(7):527-32. PubMed ID: 16721749
[TBL] [Abstract][Full Text] [Related]
14. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
[TBL] [Abstract][Full Text] [Related]
15. Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer.
Ohtsuka T; Liu XF; Koga Y; Kitajima Y; Nakafusa Y; Ha CW; Lee SW; Miyazaki K
Oncogene; 2006 Mar; 25(12):1807-11. PubMed ID: 16331272
[TBL] [Abstract][Full Text] [Related]
16. P53 abnormalities and outcomes in colorectal cancer: a systematic review.
Smith FM; Stephens RB; Kennedy MJ; Reynolds JV
Br J Cancer; 2005 May; 92(9):1813. PubMed ID: 15856032
[No Abstract] [Full Text] [Related]
17. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.
Zhu ZZ; Liu B; Wang AZ; Jia HR; Jin XX; He XL; Hou LF; Zhu GS
J Zhejiang Univ Sci B; 2008 Nov; 9(11):847-52. PubMed ID: 18988302
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid synthase hyperactivation in human colorectal cancer: relationship with tumor side and sex.
Notarnicola M; Altomare DF; Calvani M; Orlando A; Bifulco M; D'Attoma B; Caruso MG
Oncology; 2006; 71(5-6):327-32. PubMed ID: 17687193
[TBL] [Abstract][Full Text] [Related]
19. Clustered DNA lesion sites as a source of mutations during human colorectal tumourigenesis.
Radford IR; Lobachevsky PN
Mutat Res; 2008 Nov; 646(1-2):60-8. PubMed ID: 18824008
[TBL] [Abstract][Full Text] [Related]
20. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
